poisar

Stocks · News reference

BioCryst Pharmaceuticals Reports Third Quarter 2026 Financial Results

Fiscal.ai

BioCryst Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2026, highlighting continued growth of its ORLADEYO therapy.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — BIOCRYST PHARMACEUTICALS INC (BCRX)

    Filed: 2026-11-04 AccNo: 0001171843-26-007097 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits